Angle PLC
LSE:AGL
Angle PLC
ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.
ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.
Commercial Progress: ANGLE made significant strides in commercialization, including completing three major pharma projects and announcing its first large med tech collaboration with Myriad Genetics.
Revenue Pressure: Revenues were negatively impacted by challenging market conditions, with pharma revenue down and product revenue flat compared to the prior year.
Cost Control: Operating expenditure was reduced by 12%, and the comprehensive loss was cut by 7%. Cash runway remains into Q1 2026.
Innovation: ANGLE developed a unique DNA dual analysis solution with Illumina, offering better cancer mutation detection than standard ctDNA alone.
NHS Engagement: Serious discussions began with the NHS about evaluating ANGLE's technology in lung cancer diagnostics, potentially expanding to other cancers.
Pipeline & Outlook: A robust pipeline of pharma and med tech partnerships is developing, though decision-making is currently delayed at some large corporates.
Future Funding: Access to additional funding remains a key focus for the second half, with multiple options under consideration.
